Which MS treatments best help patients at work?

The latest disease-modifying drugs for multiple sclerosis (MS) are more likely to enable a patient to hold down a job than traditional injectable treatments, Australian researchers say.

High-efficacy agents such as natalizumab, fingolimod, alemtuzumab and mitoxantrone were two to three times better than earlier therapies such as beta-interferons and glatiramer acetate for improving a patient’s ability to work, they say.

The researchers, led by the Menzies Institute of Medical Research in Hobart, analysed questionnaires filled in by nearly 900 MS patients contributing to the Australian MS